All In Biotech

Drug Trial Radar · NCT05118750

ALTO-300 in Depression

An Open-label Study of ALTO-300 in Adults With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Apr 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

91

Actual

Start

Dec 13, 2021

Primary completion

May 5, 2023

Study completion May 9, 2023

Sponsor

Lead sponsor
Alto NeuroscienceIndustry
Sponsor type
Industry
First posted
Nov 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.

Conditions

  • Major Depressive Disorder

Interventions

  • ALTO-300 oral (PO) tabletDrug

    One tablet daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To understand the relationship between baseline biology and clinical outcome to ALTO-300 using the Montgomery-Åsberg Depression Rating Scale (MADRS)Time frame: Measured 6 times over 8 weeks
  2. To understand the relationship between baseline biology and clinical outcome to ALTO-300 using the Clinical Global Impression scale - Severity (CGI-S)Time frame: Measured 6 times over 8 weeks
  3. To evaluate the safety of ALTO-300Time frame: From the signing of the ICF until the follow-up visit (up to 12 weeks)
  4. To evaluate the safety of ALTO-300Time frame: From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Site 153

    Culver City, California

  • Site 103

    Sacramento, California

  • Site 158

    Santee, California

  • Site 159

    Clermont, Florida

  • Site 161

    Okeechobee, Florida

  • Site 137

    Noblesville, Indiana

  • Site 166

    Saint Charles, Missouri

  • Site 132

    New York, New York

  • Site 102

    Dallas, Texas

  • Site 165

    DeSoto, Texas

  • Site 147

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.